Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869191 | 0.94 | PRKDC (0.56) | PRKDCPIK3CAPIK3CGRIPK1GPR142 | |
| SCHEMBL3752585 | 0.92 | PRKDC (0.57) | PRKDCPIK3CAPIK3CGRIPK1GPR142 | |
| SCHEMBL3756049 | 0.92 | PRKDC (0.56) | PRKDCPIK3CAPIK3CGRIPK1 | |
| SCHEMBL3755747 | 0.92 | PRKDC (0.56) | PRKDCPIK3CAPIK3CGRIPK1 | |
| SCHEMBL3750502 | 0.92 | PRKDC (0.55) | PRKDCPIK3CAPIK3CGRIPK1GPR142 | |
| SCHEMBL3747626 | 0.91 | PRKDC (0.54) | PRKDCPIK3CAPIK3CGRIPK1GPR142 | |
| SCHEMBL3755143 | 0.91 | PRKDC (0.54) | PRKDCPIK3CAPIK3CGRIPK1GPR142 | |
| SCHEMBL3754870 | 0.91 | PRKDC (0.56) | PRKDCPIK3CAPIK3CGRIPK1GPR142 | |
| SCHEMBL3751119 | 0.91 | PRKDC (0.53) | PRKDCPIK3CAPIK3CGRIPK1GPR142 | |
| SCHEMBL3760514 | 0.90 | PRKDC (0.54) | PRKDCPIK3CAPIK3CGRIPK1GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PRKDC 480/4885PIK3CA 16/4885PIK3CG 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.